AMD

R100 is an adeno-associated virus (AAV) vector invented by 4DMT for intravitreal delivery.

Researchers found that better general health and ability to drive were each separately associated with significantly lower risk of death among individuals with AMD.

While these injections are the standard treatment for this patient population, the investigators found a subgroup of patients who had severe visual loss between 2 consecutive intravitreal injections.

This investigational new drug application was cleared for the company’s phase I/II clinical trial.

The study demonstrated a meaningful increase in the long chain and very long chain polyunsaturated fatty acids whose deficit is associated with dry AMD.

The company announced the Complete Letter Response from the FDA for the Biologics License Application for aflibercept 8 mg is “solely due to an ongoing review of inspection findings at a third-party filler.”

The study will include 100 patients with the aim of determining effective and ineffective standards of eye injections for AMD to better personalize future medical evaluations.

Real-world patients often fail to achieve and retain the visual acuity results observed in clinical trials for anti–VEGF-A therapy. Broader therapeutic inhibition of additional angiogenic factors VEGF-C and VEGF-D could change that.

EyeBio has begun the dosing of the first participants in its Phase 1b/2 AMARONE clinical trial for the treatment of diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD).

This two-in-one option, PreserVision AREDS 2 Formula eye vitamins plus CoQ10 combines the exact nutrient formula recommended by the National Eye Institute (NEI) to help reduce the risk of moderate to advanced Age-related Macular Degeneration (AMD) progression.

The company’s pipeline includes treatments for XLRP, AMD, and cone-rod dystrophy (CRD).

Arshad M. Khanani, MD, MA, MASRS, shares long-term data outcomes of patients treated with the port delivery system for neovascular AMD.

RAFARM and BioNanoSim have entered into an agreement to create a new Opthalmic company: BNS Opthalmics (BNSO).

Ocular Therapeutix is scheduled to present trial results as well as participate in a panel discussion and sponsor a presentation at the 2023 Clinical Trials at the Summit Annual Meeting.

CLS-AX is a proprietary suspension of axitinib for suprachoroidal injection being assessed for the treatment of neovascular age-related macular degeneration (wet AMD).

World No Tobacco Day helps to bring focus onto risk factors and symptoms of early vision loss linked to smoking.

VABYSMO is the first treatment for wet AMD and DME in Canada that acts by targeting both VEGF-A and Ang-2, two key drivers of vascular instability that have been associated with vision-threatening retinal conditions.

The company is currently developing treatments for age related macular degeneration as injections and eye drops, among others.

The iPredictTM AI Eye Screening System will provide a fully automated age-related macular degeneration (AMD) screening report in less than 60 seconds.

PMC-403 is a first-in-class antibody that activates TIE2, a receptor specifically expressed in vascular endothelial cells. The clinical trial will take place in multiple hospitals in South Korea.

AIV007 is a broad spectrum tyrosine kinase inhibitor, targeting the convergence of fibrosis, angiogenesis, and inflammation.

Leo P. Semes, OD, shared his insights on early detection of age-related macular degeneration during the 17th annual Controversies in Modern Eye Care symposium in Los Angeles, California.

Espansione Group announced the second wave of its major research effort for the prevention and management of dry AMD.

The treatment is designed to slow the rate of degeneration of retinal cells, slowing the progression of geographic atrophy.

Researchers collaborate to study AMD through database of donor eye tissue to provide new data for study and future treatment targeting.

Researchers in Australia have identified genes that play a role in oxidative stress and aging in the macula.

D-4517.2 is a novel precision nanomedicine that inhibits neovascularization by targeting activated microglia and hypertrophic retinal pigment cells, cells responsible for the increased vascularization associated with neovascular age-related macular degeneration (wet AMD) and diabetic macular edema (DME).

Genentech announced post-hoc data indicating treatment with faricimab-svoa (Vabysmo) led to greater and faster drying of retinal fluid with fewer injections for the treatments of wet AMD and DME, when compared to aflibercept.

VLTR-557, Valitor's long-acting anti-VEGF biologic in development for durable wet age-related macular degeneration (AMD) treatment, showed that a single intravitreal (ITV) injection has potential to maintain clinical efficacy for more than six months.

Investigators found that Photobiomodulation may be a valid therapeutic option to treat large soft drusen and drusenoid pigment epithelial detachments in dry AMD and may slow the natural disease course.